TY - T1的全身,肌肉反应有氧运动训练和退出在老化,慢性阻塞性肺病JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01507 -2021欧元SP - 2101507 AU -洛娜·e·拉蒂默盟Dumitru Constantin-Teodosiu AU - Bhavesh Popat AU - Despina江诗丹顿盟——Linzy Houchen-Wolloff盟迈克尔·c·施泰纳-夏洛特·e·博尔顿盟盟-保罗·l·Greenhaff Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/09/24/13993003.01507 - 2021. -抽象N2 -慢性阻塞性肺病患者表现出更低的峰值耗氧量(V̇O2PEAK),改变肌肉代谢及运动耐量受损而同年龄组。这些特征是否反映肌肉水平去适应作用(影响通气约束)和/或功能障碍在线粒体ATP生产能力是讨论。通过研究有氧运动训练(让)匹配的相对强度和随后的练习戒断期(EW)我们旨在阐明全身肌肉线粒体健康年轻的响应能力(衔接),健康成年(HO)和慢性阻塞性肺病志愿者全身锻炼。HY (n = 10), HO (n = 10)和慢性阻塞性肺病(n = 20)志愿者学习之前,8周后让(65% V̇O2PEAK)和4周后电子战。V̇O2PEAK、肌肉最大线粒体ATP生产速度(MAPR),线粒体,线粒体DNA的拷贝数和大量的59针对性燃料代谢mrna跨度为测定。肌肉MAPR(正常的线粒体内容)没有不同基质组合在HO HY在基线和慢性阻塞性肺病,但线粒体DNA拷贝数相对于nuclear-encoded辅助基因在HY(平均数±标准差)大(804±67)比(631±69),p = 0.041。让增加V̇O2PEAK HO (17%, p = 0.002)和(0.001 21%,术中;)为什么但不是慢性阻塞性肺病(p = 0.603)。肌肉MAPR的棕榈酸酯增加培训HO (57%, p = 0.041)和HY (56%, p = 0.003),减少与电子战HO (−45%, p = 0.036)和HY (−30%, p = 0.016),但在慢性阻塞性肺病持平(p = 0.594)。线粒体DNA拷贝数增加而让在HY (66%, p = 0.001),但不是HO (p = 0.081)或慢性阻塞性肺病(p = 0.132)。 The observed changes in muscle mRNA abundance were similar in all groups after AET and EW.Intrinsic mitochondrial function was not impaired by ageing or COPD in the untrained state. Whole-body and muscle mitochondrial responses to AET were robust in HY, evident in HO, but deficient in COPD. All showed robust muscle mRNA responses. Higher relative exercise intensities during whole-body training may be needed to maximise whole-body and muscle mitochondrial adaptation in COPD.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of Interest: Lorna E. Latimer has nothing to disclose.Conflict of Interest: Dumitru Constantin-Teodosiu has nothing to disclose.Conflict of Interest: Bhavesh Popat has nothing to disclose.Conflict of Interest: Despina Constantin has nothing to disclose.Conflict of Interest: Linzy Houchen-Wolloff has nothing to disclose.Conflict of Interest: Charlotte Bolton reports, during the course of the study, funding from MRC/ABPI COPD consortium and NIHR; grants or contracts from British Lung Foundation, H2020, GSK, Pfizer; travel support from Chiesi, outside the submitted work.Conflict of Interest: Michael C. Steiner has nothing to disclose.Conflict of Interest: Paul L. Greenhaff has nothing to disclose. ER -